drugset / Trial / NCT03817502

Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia

NCT03817502

Phase 3 Recruiting 330 enrolled Gedeon Richter Plc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of cariprazine in the treatment of schizophrenia in the adolescent population.

Timeline

Start
2019-06-06
Primary completion
2026-12-15
Completion
2026-12-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Cariprazine Small molecule 1.5 mg Oral
Subject Cariprazine Small molecule 4.5 mg Oral

Indications